Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
alopecia, American, Anima, areata, ARMO, AurKa, Biotech, BIVIP, Blueprint, caption, checkpoint, chemotherapy, choose, conduct, delivery, demonstrated, discovery, displaced, episodic, erosion, experienced, force, Genentech, House, Imrestor, Informationsstelle, IPO, Mirikizumab, neuroscience, ownership, path, pegilodecakin, PEGylated, Pharma, plaque, pork, regulation, reopen, reversed, RFI, sentence, Siglion, stake, suspension, tumor, unpredictable, White, wide
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 2002 Lilly Stock Plan, As Amended
- 12 Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges
- 31.1 Rule 13A-14(A) Certification of David A. Ricks, Chairman, President, & CEO
- 31.2 Rule 13A-14(A) Certification of Joshua L. Smiley, SR Vice President and CFO
- 32 Section 1350 Certification
- Download Excel data file
- View Excel data file
Related press release
Associated LLY transcripts
LLY similar filings
Filing view
External links
EXHIBIT 12. Statement Re: Computation of Ratio of Earnings to Fixed Charges
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
Six Months Ended June 30, | Years Ended December 31, | |||||||||||||||||||||||
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||
Consolidated pretax income | $ | 1,445.8 | $ | 2,197.4 | $ | 3,374.0 | $ | 2,790.0 | $ | 3,000.3 | $ | 5,889.3 | ||||||||||||
Interest (1) | 149.5 | 282.3 | 232.9 | 216.0 | 187.1 | 184.2 | ||||||||||||||||||
Less interest capitalized during the period | (25.0 | ) | (57.3 | ) | (47.7 | ) | (54.8 | ) | (38.3 | ) | (24.1 | ) | ||||||||||||
Earnings | $ | 1,570.3 | $ | 2,422.4 | $ | 3,559.2 | $ | 2,951.2 | $ | 3,149.1 | $ | 6,049.4 | ||||||||||||
Fixed charges | $ | 149.5 | $ | 282.3 | $ | 232.9 | $ | 216.0 | $ | 187.1 | $ | 184.2 | ||||||||||||
Ratio of earnings to fixed charges | 10.5 | 8.6 | 15.3 | 13.7 | 16.8 | 32.8 |
(1) | Interest is based upon interest expense reported as such in the consolidated condensed statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense. |